Linked-color imaging with computer-aided detection and the proximal adenoma miss rate: a randomized tandem trial.

Gastrointest EndoscApr 18, 2026 (epub)
Clinical ResearchGastroenterology

Naohiko Akimoto, Osamu Goto, Takayoshi Nishimoto et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of linked-color imaging (LCI) with computer-aided detection (CADe) in reducing adenoma miss rates during colonoscopy. Conducted at a single center with 232 participants, the study found that the adenoma miss rate was significantly lower in the LCI/CADe group (20%) compared to conventional white-light imaging (39%), with a P-value of .001.

Key findings

  • Adenoma miss rate was 20% in LCI/CADe group vs 39% in WLI group (P = .001).
  • Polyp miss rate was significantly lower in LCI/CADe group at 18% compared to 42% in WLI (P < .001).
  • Diminutive adenoma miss rate was 21% in LCI/CADe vs 42% in WLI (P = .003).
  • Advanced adenoma miss rate was 0% in LCI/CADe compared to 30% in WLI.

Why it matters

The findings suggest that LCI combined with CADe significantly enhances the detection of adenomas during colonoscopy, potentially leading to improved patient outcomes by reducing the risk of missed lesions.

Source

PubMed · PMID 42009205

Published in Gastrointest Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.